Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

Crizotinib is one of the molecularly-targeted agents targeted against anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Although its effects appear to be promising, crizotinib may cause adverse effects in patients with ALK-rearranged NSCLC. Hepatic laboratory abnormalities are frequently observed with crizotinib and treatment discontinuation is occasionally required. We herein report the case of a 51-year-old woman diagnosed with relapsed ALK-rearranged NSCLC, who received crizotinib as second-line systemic chemotherapy. After 17 days of crizotinib therapy, the patient developed grade >3 hepatotoxicity. Treatment discontinuation improved the laboratory abnormalities and fifth-line oral desensitization with crizotinib achieved successful response without hepatotoxicity. Therefore, oral desensitization with crizotinib may be a viable option following crizotinib-induced hepatitis.

[1]  Weiwei Tan,et al.  Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non–Small Cell Lung Cancer , 2016, Clinical Cancer Research.

[2]  X. Humbert,et al.  Successful treatment with ceritinib after crizotinib induced hepatitis. , 2016, Lung cancer.

[3]  K. Arnaoutakis Crizotinib in ROS1-rearranged non-small-cell lung cancer. , 2015, The New England journal of medicine.

[4]  Shingo Matsumoto,et al.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. , 2015, Translational lung cancer research.

[5]  F. Cappuzzo,et al.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.

[6]  A. Shaw,et al.  Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib. , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  R. Seo,et al.  Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma. , 2014, Japanese journal of clinical oncology.

[8]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[9]  Y. Ohe,et al.  CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. , 2013, The Lancet. Oncology.

[10]  D. Larrey,et al.  Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. , 2013, Clinics and research in hepatology and gastroenterology.